The main purpose of this study is to identify a safe and potentially effective dose of tuspetinib to be used in future studies in study participants diagnosed …

Leukemia, Myeloid, AcuteRefractory AMLRelapsed Adult AML+2 more

~Estimated

~$10 – $8,750

Aptose Biosciences Inc.NCT03850574

Phase 1

A Phase 1 Study of BXCL701 in Relapsed/Refractory Acute Myeloid Leukemia or Relapsed/Refractory Myelodysplastic Syndrome With Excess Blasts - 2

The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or …

Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2

~Estimated

~$10 – $7,500

Eric Stephen Winer, MDNCT05703542